GSK 3342830

Drug Profile

GSK 3342830

Alternative Names: GSK3342830

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Developer GlaxoSmithKline; Shionogi
  • Class Anti-infectives; Antibacterials; Cephalosporins; Cephems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 30 Nov 2017 GlaxoSmithKline terminates a phase I trial in Gram-negative infections (In volunteers) in Australia as study data is currently under review (IV) (NCT02751424)
  • 15 Mar 2017 GlaxoSmithKline suspends participant recruitment in a phase I trial in Gram-negative infections (In volunteers) in Australia (IV) (NCT02751424)
  • 01 Jun 2016 Phase-I clinical trials in Gram-negative infections (In volunteers) in Australia (IV) (NCT02751424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top